Compare ImmunityBio Inc. Common Stock (IBRX) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ImmunityBio Inc. Common Stock vs Xylem, Inc. — how do they compare? ImmunityBio Inc. Common Stock trades at $10.64 (market cap $10.51B), while Xylem, Inc. trades at $102 (market cap $23.81B). The key difference: Xylem, Inc. is far larger — about 2.3× ImmunityBio Inc. Common Stock's market cap, and Xylem, Inc. pays a 1.69% dividend while ImmunityBio Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold ImmunityBio Inc. Common Stock for 0 Days and Xylem, Inc. for 50 Days on average.
| IBRX | XYL | |
|---|---|---|
Market Cap | $10.51B | $23.81B |
Volume | 10,445,785 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $11.55 | $152.95 |
52-Week Low | $1.98 | $100.92 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $10.97B | $25.59B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
XYL trades at $101.83, down 2.63% today, with a bearish technical signal from moving averages. The company shows strong fundamentals with consistent revenue growth from $5.5B in 2022 to $9.0B in 2025 and net income margin expanding to 10.59%. Recent acquisitions of Cornell Pump and Roper Pump strengthen its industrial water solutions portfolio. XYL has beaten earnings estimates for three consecutive quarters, with Q3 2026 results expected on October 27, 2026.
Analyst consensus is mixed with 47.5% buy ratings and a $149.13 price target suggesting 46% upside. Key risks include China market weakness and increased debt from recent acquisitions. The stock offers value with reasonable P/E of 24.28 and strong cash flow generation, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ImmunityBio Inc. Common Stock
ImmunityBio develops immune-based therapies for cancer and infectious diseases. Its programs are designed to activate and strengthen the body’s immune response.
Read more on IBRX →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
